The University of Chicago Header Logo

Refractory metastatic Crohn's disease responsive to ustekinumab dose intensification.

Refractory metastatic Crohn's disease responsive to ustekinumab dose intensification. JAAD Case Rep. 2023 Feb; 32:65-67.

View in: PubMed